PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition

Jennifer M Spangle1, Thanh Von2,3, Dean C Pavlick4

  • 1Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115; jennifer.spangle@emory.edu thomas_roberts@dfci.harvard.edu.

Insights

New PIK3CA C-terminal mutations drive cancer and respond to p110α-selective inhibitors. These findings suggest potential benefits for patients with PIK3CA-mutated breast and other cancers treated with targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • PIK3CA hotspot mutations are known oncogenic drivers in cancer.
  • Many PIK3CA mutations remain uncharacterized, limiting targeted therapy development.
  • PI3K pathway dysregulation is crucial in cancer progression.

Purpose of the Study:

  • To characterize novel PIK3CA C-terminal mutations.
  • To assess the oncogenic potential and therapeutic sensitivity of these mutations.
  • To evaluate the efficacy of p110α-selective inhibitors against these mutations.

Main Methods:

  • Analysis of PIK3CA C-terminal mutations, including nucleotide insertions.
  • In vitro and in vivo studies to assess oncogenic transformation.
  • Pharmacologic inhibition using p110α-selective agents.
  • Assessment of p85 and Ras association with mutant p110α proteins.

Main Results:

  • Identified PIK3CA C-terminal mutations causing frame-shifts and extended protein products.
  • These mutations, though infrequent, drive oncogenic transformation in vitro and in vivo.
  • Oncogenicity depends on p85 association but not Ras association.
  • P110α-selective inhibition effectively blocks transformation in affected cells and tumors.

Conclusions:

  • PIK3CA C-terminal frameshift mutations are oncogenic drivers.
  • These mutations sensitize tumors to p110α-selective inhibitors.
  • Patients with PIK3CA C-terminal frameshift mutations may benefit from therapies like alpelisib.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.8K
Point and Frameshift Mutations01:30

Point and Frameshift Mutations

Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...
608